Revolutionizing Pediatric Growth Hormone Deficiency Treatment

[madman]

To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Accept third party cookies

Rick Hawkins, CEO and chairman of Lumos Pharma, discusses the company’s late-stage development of a small molecule for the treatment of pediatric growth hormone deficiency (PGHD). This innovative oral mini tablet aims to revolutionize the current standard of care, which involves daily injections for several years. The potential impact on the $5 billion global growth hormone market could be significant if the trial results are positive.


Highlights:

• Rick Hawkins, CEO and chairman of Lumos Pharma, discusses the company’s late-stage development of a small molecule for PGHD.
• The global phase 2B trial results for the oral mini tablet in the treatment of PGHD are forthcoming.
• The current standard of care for PGHD involves daily injections for several years.
• The growth hormone market is valued at approximately $5 billion globally.
• Injectable growth hormone is the current standard treatment for PGHD and other growth hormone disorders.
• Lumos Pharma’s innovation aims to provide a daily oral mini tablet as an alternative to daily injections for PGHD patients.